Every cancer originates from a single cell. During expansion of the neoplastic cell population, individual cells acquire genetic and phenotypic differences from each other. Here, to investigate the nature and extent of intra-tumour diversification, we characterized organoids derived from multiple single cells from three colorectal cancers as well as from adjacent normal intestinal crypts. Colorectal cancer cells showed extensive mutational diversification and carried several times more somatic mutations than normal colorectal cells. Most mutations were acquired during the final dominant clonal expansion of the cancer and resulted from mutational processes that are absent from normal colorectal cells. Intra-tumour diversification of DNA methylation and transcriptome states also occurred; these alterations were cell-autonomous, stable, and followed the phylogenetic tree of each cancer. There were marked differences in responses to anticancer drugs between even closely related cells of the same tumour. The results indicate that colorectal cancer cells experience substantial increases in somatic mutation rate compared to normal colorectal cells, and that genetic diversification of each cancer is accompanied by pervasive, stable and inherited differences in the biological states of individual cancer cells.
Recent studies have explored genetic diversification within cancer cell populations by identifying mutations shared by subpopulations of cells within the cancer clone [1] [2] [3] [4] [5] [6] . In principle, however, the extent of intra-tumour genetic diversity is most comprehensively revealed by single-cancer-cell DNA sequencing, which can potentially identify all mutations, including those that arose in the distant past, those that occurred very recently, and those not present in any other cell 7, 8 . Despite recent advances, however, single-cell genome sequencing remains dependent on prior whole-genome amplification, which is associated with incomplete genome coverage and artefactual mutations 9 . Diversification of epigenomic, transcriptomic, proteomic and metabolic states, and of functional states such as resistance to anticancer therapy, may also occur during expansion of the neoplastic cell population [10] [11] [12] [13] . Methylation, gene expression and drug response data have previously been obtained from multiple cells from individual tumours, but the collection of all these features together with accurate genome information from the same single cells has not been reported, to our knowledge [14] [15] [16] [17] [18] [19] . The origins of epigenomic and transcriptomic diversification are unclear, and there is little insight into whether these are transient or stable.
One experimental approach that enables comprehensive, systematic and integrated exploration of intra-tumour diversification is to derive immortal cell lines from multiple single cells from the same cancer 20 . These serve as proxies for the single cells from which they originate and can be subjected to extensive and multimodal characterization, thereby revealing all aspects of intra-tumour diversification retained during in vitro growth. We have recently developed protocols for derivation of clonal organoids from normal and neoplastic colorectal stem cells, and we use this strategy here to compare single cells from normal and neoplastic colorectal epithelium [21] [22] [23] [24] .
Comparison of the number of mutations in single cancer cell genomes with that in individual normal cells from the same tissue may also reveal whether alterations in somatic mutation rate and mutational process have been experienced by neoplastic cells. Substantial increases in mutation rate are known to occur during the development of cancers with DNA mismatch repair deficiency or mutations in genes encoding DNA polymerases 25 . Whether mutation rate increases are common in cancers without these specific abnormalities is, however, currently unknown and a matter of controversy [26] [27] [28] [29] [30] .
Clonal organoid derivation
Colorectal cancers from three previously untreated individuals (P1, P2 and P3) were each dissected into 4-6 pieces (Extended Data Fig. 1 ). Organoid cultures were derived from cell suspensions made separately from each piece and were maintained for up to one week without passage. Subsequently, individual organoids were disaggregated and flowsorted to obtain single cells from which clonal cancer organoids were established. For each individual, organoids were also derived from single crypts in normal colorectal epithelium from the same resection specimens. A crypt derives from a single stem cell that has been estimated to exist several months before crypt isolation 24, 31 . The coding regions of 360 known cancer genes were sequenced in all normal and cancer-derived clonal organoids for likely driver mutations and a subset were whole-genome sequenced. Somatic mutations
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were identified by comparison with the sequences of DNA extracted from pieces of normal colorectal tissue. The overwhelming majority of somatic mutations identified in this way are likely to have occurred in vivo and not during in vitro culture (Extended Data Fig. 2c ). Clonal organoids were also subjected to analysis of DNA methylation state at 470,000 CpG sites, RNA sequencing (RNA-seq), and were assessed for response to several anticancer therapeutics.
Phylogenetic trees of somatic mutations
Using the catalogues of somatic mutations from clonal organoids, we derived cell phylogenetic trees for each individual (Fig. 1a-c and Extended Data Figs. 3-6 ). The structures of the trees generally recapitulated the geographic origins of the clonal organoids within each cancer, with more closely related branches originating from the same tumour pieces. However, organoids within each piece continued to exhibit extensive genetic diversification: for example, in organoid clones isolated from tumour section P3.T3, at least 40% of mutations were not shared with other clones from this piece (Extended Data Fig. 1o ).
In the trunk of the cancer cell phylogenetic tree of P1, we identified likely driver mutations in BRAF (V600E), PIK3CA (E81K) and ACVR2A (protein-truncating small indel). All cancer clones from this individual also showed microsatellite instability characteristic of DNA mismatch repair deficiency and hypermethylation of the MLH1 promoter (the likely cause of this instability) (Extended Data Fig. 7 ). In addition, there were likely driver truncating mutations in PTEN and RNF43 that were restricted to subsets of branches of the tree. In P2, two protein-truncating APC mutations and a homozygous splice site TP53 mutation were present in the cancer trunk. In P3, a KRAS mutation (A146T) and two truncating APC mutations were present in the cancer trunk, and a TP53 in-frame deletion was present in a subset of the branches. No driver mutations or MLH1 methylation were observed in clonal organoids derived from normal colon epithelium from the three patients.
Mutation load in normal and cancer cells
A mean of 3,792 base substitutions was found in normal organoid clones derived from P1, 3,172 from P2 and 3,621 from P3 (Fig. 2) , as previously reported 24 . The mean number of base substitutions in cancer-derived clones was higher in all three individuals: 72,398 in P1, 22,291 in P2 and 14,209 in P3. There were also substantial differences in the number of small indels and genome rearrangements. A mean of 227 small indels was observed in clones derived from normal colorectal epithelium from P1, 130 from P2 and 167 from P3. By comparison, the mean number of indels was 27,893 in cancer clones from P1, 1,485 from P2 and 2,021 from P3. There was a mean of one genome rearrangement in clonal organoids derived from normal colorectal epithelial cells contrasting with means in cancer-derived clonal organoids of 71 rearrangements from P1, 176 from P2 and 67 from P3. As the normal and cancer clones are derived from cells obtained from each individual at the same times, increases in somatic base substitution, small indel and genome rearrangement mutation rates are likely to have occurred in the lineages from fertilized egg to cancer cell, including in the two cancers that were proficient in DNA mismatch repair. Most of the additional mutation loads in cancer cells were acquired in the branches of the cancer phylogenetic tree rather than the trunk and therefore occurred following the last dominant clonal expansion within the cancer cell population.
Mutational signatures
We extracted mutational signatures and estimated the contributions of each signature to each segment of the phylogenetic trees. Eight base substitution mutational signatures were found (referred to according to the nomenclature in COSMIC http://cancer.sanger.ac.uk/cosmic/signatures). T2   T1   T4   T3   N   T1   T2  T2   T6.2subclone   T5  T5   T6   T4  T4   N   T1   T2   T3 
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These include the previously described signatures 1, 5, 6, 17, 18, 20 and 26 and a signature that has not been previously encountered 32 (see also Supplementary Notes section 5). Each mutational signature can be regarded as the outcome of a mutational process, which includes components of DNA damage or modification, DNA repair (or absence of it) and DNA replication, with each component potentially influencing the profile of the signature. Signature 1 is likely to result from deamination of 5-methylcytosine to thymine and has been reported to act in a 'clock-like' manner, with mutations accumulated continuously over the lifetime of an individual at different rates in different tissues. The number of signature 1 mutations is proposed to correlate with the number of mitotic divisions 33 . Signature 5 is of uncertain origin and also shows accumulation of mutations in a clock-like manner, with different rates in different tissues, although the rates do not correlate with those of signature 1 33 . Signatures 1 and 5 are found in most human cancers and probably in most normal cells 24, 33 . Signature 1 dominated and, with signature 5, accounted for the large majority of mutations in normal colorectal stem cells 24 ( Fig. 1 ). Signature 1 also dominated in the trunks of the cancer phylogenetic trees, presumably reflecting, at least in part, the long segment of normal cell lineage from the fertilized egg to the cell in which the first cancer driver mutation was acquired. However, in each of the three cancer trunks, signatures 17 and/or 18 also showed contributions (which were not detectable in the normal clonal organoids). Signatures 17 and 18 have been found in many cancer types and have uncertain mechanisms, although signature 18 may be related to DNA damage induced by reactive oxygen species and/or by deficiency of base excision repair.
A different pattern of signature contributions was seen in the branches of the three cancer phylogenetic trees (Fig. 1) . In P1, the mutations were predominantly of signatures 6, 20, 26 and indels; in P2, signatures 5, 17, 18, and indels; and in P3, signatures 5, 18, indels and a new signature predominantly characterized by T > G, T > A and T > C mutations at NTA and NTT trinucleotides (the mutated base is underlined; Extended Data Fig. 2d ). The last signature occurred in all clones carrying a small in-frame deletion in TP53, but its relationship to this putative driver mutation is unknown. With regard to structural changes, P1 cancer clones carried deletions, inversions and tandem duplications, but few translocations, and their copy number profiles were relatively flat ( Fig. 1 b, Clustering analysis of transcriptome state in each clonal organoid using RNA-seq (n = 73 clones). c. Phylogenetic trees based on methylation data (top), mutation data (middle) and expression data (bottom). Distances between mutation tree and methylation or expression tree topologies are expressed as subtree prune and regraft distance (SPR).
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There were more signature 1 mutations in each cancer organoid than in normal organoids from the same individuals ( Fig. 1 and Extended Data Fig. 2e ). Assuming that the clock-like correlation between the number of signature 1 mutations and number of mitoses undergone in normal cells is maintained at the same rate during neoplastic cell proliferation, we estimate that cancer cells from individual P1 have undergone 1.9 (± 0.5) (s.d.) times as many mitoses as normal cells, cancer cells from individual P2 2.5 (± 0.2) times as many, and from individual P3 1.7 (± 0.2) times as many. An alternative explanation for the increase in signature 1 mutations in cancer cells is increased DNA methylation in cancer cells. However, cancer organoids were generally hypomethylated compared to normal cells (Extended Data Fig. 8b ). In the distal branches of the phylogenetic trees (that is, during the most recent phases of cancer growth) the base substitution mutation rates per mitosis (as estimated by the total number of mutations divided by the number of signature 1 mutations) were markedly increased compared to normal cells (estimated 100-fold in P1, which is DNA mismatchrepair deficient, and tenfold in P2 and P3, which are mismatch-repair proficient). Thus, assuming that these estimates of past mitoses undergone are correct, the increases in base substitution, indel and genome rearrangement mutation rates over time also represent increases in mutation rates per mitosis.
Methylome and transcriptome
Epigenetic changes may be part of, and contribute to, the biological diversification of intra-tumour cell populations. To explore this possibility, we examined the methylation status of 470,000 CpG sites in the normal and tumour-derived clonal organoids. Organoids derived from normal stem cells from P1, P2 and P3 clustered together in principal component analyses, albeit with normal clones from each individual closer to each other than to normal clones from other individuals ( Fig. 3 and Extended Data Fig. 8a ). Clonal organoids from each colorectal cancer clustered together, with the exception of the two TP53 wild-type clones of P3, but separately from those derived from the other cancers and from normal organoids. Thus, the methylation states of normal colorectal stem cells from different individuals were relatively similar, but tumours from different individuals had developed divergent epigenetic states. For the P1 tumour, this conformed to the pattern of global hypermethylation previously termed CpG island methylator phenotype (CIMP) 25 . To investigate intra-tumour diversification of transcriptome state, we performed RNA-seq of normal colorectal epithelium and cancer-derived organoid clones. Clustering by gene expression profiles correlated well with clustering by methylation, with normal organoids from all individuals clustering together, while separate clusters existed for each cancer ( Fig. 3b and Extended Data Fig. 9a ). For each cancer we constructed phylogenetic trees based on methylation and gene expression (Fig. 3c) . The topologies of the methylation and expression trees were remarkably similar to the mutation-based trees. Thus, diversification of methylation and transcriptome state occurred within each cancer and this was apparently heritable, stable and independent of the tumour microenvironment, as it persisted after organoid culture in vitro.
Diversification of drug responses
The clonal cancer organoids were exposed in vitro to a set of drugs used to treat colorectal cancer, including the chemotherapeutic agents 5-fluorouracil (5-FU), doxorubicin and 7-ethyl-10-hydroxycamptothecin (SN-38, the active metabolite of irinotecan), and the targeted agents afatinib (an epidermal growth factor receptor (EGFR) inhibitor), nutlin-3a (a stabilizer of TP53), a MEK1/2 inhibitor and an AKT inhibitor. Different organoids from the same cancer displayed substantial and reproducible differences in IC 50 values of up to 1,000-fold (Fig. 4 and Extended Data Fig. 10a, b) , for both chemotherapeutic agents and targeted therapies. Some differences were attributable to particular somatic mutations. Notably, nutlin-3a exerted much greater growth Article reSeArcH inhibition of TP53 wild-type than mutant clones in P3 tumour organoids. Additionally, truncating mutations in RNF43, a recessive cancer gene encoding a negative regulator of the WNT pathway 34 , rendered cells highly sensitive to the WNT secretion/porcupine inhibitor IWP2 (Extended Data Fig. 10c ). The remaining variation in drug response did not, however, clearly relate to the geographical zones of origin or to the phylogenetic trees of each cancer. There were several examples of marked differences in drug sensitivity between closely related clones. For example, P2.T4.1 showed marked resistance to SN-38 compared to the other P2.T4 clones, whereas P3.T1.5 showed distinct sensitivity to 5-FU compared to all other clones from this individual (Fig. 4 and Extended Data Fig. 10a ). The mechanism underlying this diversification in biological behaviour is unclear, but there was no obvious correlation with the degree of mutational diversification.
Discussion
Previous studies have addressed particular aspects of intra-cancer diversification by profiling the transcriptome, DNA copy number state and functional responses of individual cells [14] [15] [16] 35 . To our knowledge, this is the first systematic and integrated analysis at genetic, epigenetic, transcriptomic and functional levels of multiple single-cell-derived clones from human cancers to incorporate high-quality and comprehensive description of essentially all somatic mutations present in multiple single cells. All three cancers studied, including the two DNA mismatch-repair proficient cases, clearly exhibited higher mutation burdens than normal colorectal stem cells. These are likely to result from increased mutation rates experienced during the lineages from fertilized egg to colorectal cancer cell. More comparisons of normal and colorectal cancer cells, and similar comparisons for other classes of cancer, are required for corroboration but it seems likely that increases in somatic mutation rates are common during the development of human cancers. These increases are predominantly due to recruitment of mutational processes that are inactive or marginally active in normal cells, and which dominate at later stages in the evolution of the cancer cell population. The roles of these processes in generating driver mutations, however, are unclear, as they may have started before or after acquisition of the early driver mutations in the trunks of the cancer phylogenetic trees 5 . The mechanisms underlying the increases in mutation rate in the DNA mismatch-repair proficient cancers are, for the most part, unknown. These increases may be due to somatic genetic or epigenetic changes (although these are not currently obvious), to metabolic stress attendant upon the elevated mitotic rate and other features of the neoplastic state, or to effects of the cancer cell microenvironment. Alongside intra-tumour mutational diversification, diversification of methylation state, transcriptome state and biological responses to therapeutics occur. While some methylation and transcriptome changes that occurred in vivo may have been lost during in vitro growth we were able to capture methylation and transcriptome changes that followed the evolution of the cancer through the mutational phylogenetic tree, which appeared to be stable and, at least partly, independent of the tumour cell microenvironment, as they persisted after cells were removed from the tumour. Diversification of methylation and transcriptome states and of drug responses are likely to result partly from driver mutations in cancer genes, but other, currently unknown, genetic and/or epigenetic mechanisms may be involved 36 . Future studies analysing the genomes, methylomes and transcriptomes of primary cells of a cancer will be needed to reveal all genetic, epigenetic and transcriptional variation occurring between cancer cells in vivo. Nevertheless, this study has shown the strength of the organoid system in stably retaining these characteristics and enabling functional assays on clones derived from individual cells. The analysis indicates that all three colorectal cancers contained cells resistant to most of the drugs commonly used to treat the disease. Differential drug responses between clones that are closely related both genetically and epigenetically suggest that resistance mechanisms can arise late in tumorigenesis.
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MEthodS
Human tissues. Tissue material was obtained from The Diakonessen Hospital, Utrecht. From the resected colon segment, both normal and tumour tissues were isolated. The isolated tumour tissue was subdivided into 4-5 segments. Normal tissue was taken at least 5 cm away from the tumour. All samples were obtained with informed consent and the study was approved by the ethical committee of The Diakonessen Hospital, Utrecht.
No statistical methods were used to predetermine sample size. The experiments were not randomized and the investigators were not blinded to allocation during experiments and outcome assessment. Human organoid culture. Human normal and tumour colon organoids were established and maintained as described from isolated colonic epithelium 21, 22 . In brief, long-term normal colonic organoid culture required human intestinal stem cell medium (HISM) composed of advanced DMEM/F12 (AdMEM) with penicillin/streptomycin, 10 mM HEPES, 1×GlutaMAX, 1×B27 (Invitrogen) and 1 µM N-acetylcysteine (SIGMA), supplemented with 50 ng ml −1 human recombinant EGF (Peprotech), 0.5 µM A83-01 (Tocris), 3 µM SB202190 (SIGMA), 1 µM nicotinamide (SIGMA), 10 nM prostaglandin E2,Wnt3A-conditioned medium (CM) (50% final concentration), Noggin-CM (10% final concentration), and R-Spondin1-CM (10% final concentration). Tumour organoids were cultured in medium containing only EGF, Noggin-CM, R-Spondin1-CM and A83-01. Establishment of clonal organoids. For clonal organoids from normal crypts, isolated single crypts were embedded in 10 µl Matrigel and cultured in HISM medium. For clonal tumour organoid cultures, tumour cell suspensions were cultured for 7-14 days in HISM without Wnt3A-CM. Then, 10-15 individual organoids were picked and separately dissociated into single cells by TryPLE express (Thermo Fisher), washed and suspended in AdMEM containing propidium iodide (PI). Forty-eight single cells were sorted into tumour organoid medium (HISM plus 10 µM ROCK inhibitor Y-27632 (Tocris BioScience); no Wnt-CM) from each tumour organoid. Sorting was based on FCS area/FCS peak and PIneg/FCS area using a Moflo machine (Beckman Coulter). Sorted cells were spun down at 1,000g at 4 °C for 5 min, after which single cells were each embedded into 10 µl of basement membrane extract (BME, Amsbio) and seeded into 96-well plates at a ratio of 1 cell per well. The gel was left to solidify in a 37 °C incubator after HISM (no Wnt3A-CM) was added. Y-27632 was added to the medium for the first week after sorting. For each original tumour organoid, a single clonal organoid was selected and expanded for further study and for preparing frozen stocks. Culturing times and plating efficiencies are listed for each organoid in Supplementary Datafile S1. Histology procedures. Tissues were fixed in 4% formaldehyde solution overnight and embedded in paraffin. Sections were subjected to haematoxylin and eosin (H&E) and immunohistochemistry staining. The Ki67 antibody (MONX10283, Monosan) was used at 1:250 dilution. Organoid CellTiter-Glo viability assay. Tumour organoids were cultured for 5-10 days after being trypsinized into single cells in HISM without Wnt-3a-CM. The organoids were mechanically dissociated by pipetting before being resuspended in 5% BME/growth medium (25 × 10 3 organoids per ml). Before seeding, 10 µl BME was dispensed into 384-well plates, and then 30 µl growth medium containing organoids was dispensed into each plate (at about 750 organoids per well. Drug screening was carried out using nutlin-3a, afatinib, MEK1/2 inhibitor III, AKT inhibitor VIII, 5-FU, doxorubicin, and SN-38. Drug dilutions were performed in two series: 1) stepwise 2 fold-dilutions from 20 µM to 19.5 nM; and 2) stepwise 2 fold-dilutions from 15 µM to 29.3 nM. The measurements for these two dilution series were combined into a single curve. All drugs were dispensed by a HP-D300 automated liquid dispenser (TECAN). Samples were incubated for 6 days at 37 °C, and cell viability was measured by CellTiter-Glo 3D kit (Promega) on a SpectraMax M5e (Molecular Devices). Cell viability measurements were performed in duplicate wells for each clone. Survival ratios in drug-treated organoids were normalized to the average survival in a DMSO control. Each experiment was repeated on a different day. To assess variability between technical and biological replicates we calculated the area under the curve (AUC) for each survival curve. AUC values are calculated using the trapezoid method and are divided by the area covered by 100% survival on the y-axis and the range of the log 10 concentrations on the x-axis (Extended Data Fig. 10b ). DNA and RNA extraction. DNA and RNA were concomitantly extracted from frozen tissue samples or organoid cultures using AllPrep DNA/RNA minikit (Qiagen 80204). Whole-genome sequencing. From each individual, 7-10 tumour-derived clones were selected for whole-genome sequencing (WGS), as well as 4-5 normal-derived clones. We generated paired end sequencing reads (150 bp) using Illumina XTEN machines, resulting in ± 30× coverage per sample. Sequences were aligned to the human reference genome (NCBI build37) using BWA-MEM. Sequencing statistics are listed in Supplementary Datafile S2. Cancer gene panel sequencing. All WGS sequenced clones and 40 additional tumour-derived clones were subjected to targeted sequencing. An in-house developed cancer gene panel (CGPv3) was used, designed to pull down 360 genes that are known or suspected to play a role in cancer 3, 37 . The panel targets genes from the Cancer Gene Census (COSMIC), genes recurrently amplified or overexpressed in cancer and candidate cancer genes such as kinases from the MAP kinase signalling pathway. We performed custom RNA bait design following the manufacturer's guidelines (SureSelect, Agilent) and previously described workflows to create pulldown libraries from native genomic DNA 3, 37 . Samples were multiplexed on flow cells and subjected to paired end sequencing (75-bp reads) using Illumina HiSeq2000 machines, resulting in more than 700× coverage for the target design for tumour-derived samples and more than 2,000× coverage for normal tissue-derived samples. Sequences were aligned to the human reference genome (NCBI build37) using BWA-align. RNA sequencing. From each individual, RNA was isolated from all tumour and normal derived organoid clones and subjected to RNA-seq analysis. RNAseq libraries were prepared according to previously described workflows and sequenced on Illumina HiSeq2000 machines 38 . Between four and seven barcoded samples were pooled per library. Sequenced reads were aligned to the human reference genome (NCBI build37) with Bowtie/TopHat. Methylation arrays. Infinium HumanMethylation450 BeadChip arrays were used to characterize the methylation status of more than 450,000 CpG sites for all clones. Mutation discovery. All somatic changes in whole genome and targeted data were analysed with mutation calling pipelines developed in house (available at https:// github.com/cancerit). Substitutions. Single-base somatic substitutions were identified using CaVEMan 39 and a number of post-processing filters were applied. For each patient, the only germline reference available was healthy colorectal tissue more than 5 cm from the tumour, consisting of epithelial and connective tissue. In order to allow the discovery of a field effect 40, 41 that might have spread into the matched normal sample, we ran CaVEMan using an unmatched normal reference. Germline SNPs were removed by comparison to a panel of 75 unrelated normal samples. Additional post-processing filters were applied to these mutation calls as described 42 . For XTEN/BWA-mem aligned data we added two filters to the pipeline for the median alignment score (ASMD) ≥ 140 and the clipping index (CLPM) = 0, meaning that fewer than half of the reads should be clipped.
We then tabulated the number of mutant and wild-type reads for every mutation discovered in every sample, including the adjacent colorectal tissue. We considered only mutations that were covered by ten reads in all related clones, and mutations that were seen on at least two reads in each direction. As the adjacent normal colorectal tissue is not entirely composed of epithelium we reasoned that if there were a field effect the somatic mutations in this tissue should not be fully clonal. We therefore deducted germline mutations on the basis that they were fully clonal in the bulk normal, while mutations that were subclonal in the bulk were not removed from the analysis. To define a mutation as subclonal in the bulk, the probability of finding the observed number of mutant reads or fewer given the sequencing coverage had to be less than 0.005, based on the binomial distribution with a probability of 0.5 for autosomes. Mutations that failed to meet this criterion were considered to be germline and were removed. Indels. Indels were called using Pindel 43, 44 using the adjacent bulk colorectal tissue as a matched normal. Post processing filters were the same as for substitutions except that ASMD ≥ 140 and CLPM = 0 were not used.
Copy number. Copy number profiles were constructed for WGS samples by ASCAT 45, 46 , using adjacent healthy colorectal tissue as a matched normal. Copy number profiles of WGS analysed samples were visualized with the plotHeatmap function of the R package 'copynumber' 47 .
Rearrangements. Rearrangements were called using healthy adjacent colorectal tissue as a matched normal. Abnormally paired read pairs from WGS were grouped and filtered by read remapping using 'Brass' (https://github.com/cancerit/BRASS). Read pair clusters with 50% or more of the reads mapping to microbial sequences were removed. Candidate breakpoints were matched to copy number breakpoints defined by ASCAT within 10 kb. Rearrangements not associated with copy number breakpoints or with a copy number change of less than 0.3 were removed. Phylogenetic tree construction. The phylogeny of single-cell-derived organoids for each patient was constructed from substitutions called in WGS data. For each patient, substitutions that had been discovered by CaVEMan in any organoid from that patient were called as present or absent in each organoid using the algorithm Shearwater 48 . This algorithm compares allele frequencies of variants to a background error model derived from sequencing thousands of samples from unrelated studies on the same platform. Sequencing errors are known to occur at different frequencies across different sites of the genome 48 . By obtaining a comprehensive view of the number of variant calls at each position in unrelated normal genomes, we built an error model for each nucleotide change for each position. This method has previously been used to find variants at a low frequency 49 . Here, we compared the observed frequency of each variant to our error model. After correcting for multiple testing, only variants that were significantly mutated over the error Article reSeArcH model were kept, using a q value cutoff of 0.05. Although most true variants largely exceed this threshold, this procedure maximizes the chance of retaining variants in genomic regions that have undergone copy number changes, lowering the apparent variant allele fraction (VAF), since the Shearwater algorithm was designed to detect subclonal variants. As a further stringent filter to minimise false positive calls, variants had to be supported by at least three mutant reads to be considered by the algorithm. In this way every mutation called in an individual was genotyped as being present or absent in each sample. Phylogenies were constructed using this binary matrix of mutations present or absent in each sample. Private mutations were discarded from tree building as they are uninformative. A fake outgroup with no mutations called was generated for each individual. Phylogenies were constructed using the Phylip suite of tools 50 . The programme seqboot was used to generate 100 bootstrap replicates of each dataset by resampling the mutations with replacement. Phylogenies were then reconstructed for each bootstrap replicate by maximum parsimony using the Mix programme using the Wagner method, using the fake outgroup as a root. The jumble = 10 option was used, randomizing the order of the input samples 10 times for each bootstrap replicate. Finally, the programme Consense was used to build a consensus of all the trees that had been built for each patient, using the majority rule (extended) option. This reports, for each node in the most parsimonious tree, how many of the trees that had been built contain a node that partitions the samples into the same two groups. All nodes in each tree that relate tumour samples to each other were supported by all bootstrap replicates (Supplementary Notes). Assignment of somatic changes in WGS to the phylogenetic tree. Substitutions. Substitutions were called as present or absent in each organoid as described above. To assign these mutations to the tree, each branch of the tree was considered in turn. If a mutation was called in all the organoids that were descendants of a given branch, and in no organoids that were not descendants of the branch, mutations were assigned to that branch. Ignoring private mutations, which necessarily fit any tree, 97.7% of shared mutations fitted the tree structure from patient 1 perfectly, 89.7% fitted the tree from patient 2 perfectly, and 88.1% fitted the tree from patient 3 perfectly. The lower concordance with the tree for patients 2 and 3 reflects the increased copy number changes that have occurred in these phylogenies. Examination of the copy number state at loci where there were discordant mutations showed that the majority could be explained by deletions of those mutations in a subclone. Substitutions that did not fit the tree perfectly were therefore assigned to the most recent common ancestor of the samples in which they were called.
All substitution calls and their assignment to branches of the tree, as well as substitutions that did not fit the tree perfectly and their associated copy number states are listed in Supplementary Data file S4. Indels. Indels were called as being present or absent in each sample based on a variant allele fraction (the proportion of mutant reads at a locus) cutoff. The variant allele fraction cutoff was chosen for each patient based on a histogram of the variant allele fraction to separate the sequencing noise distribution from the distribution of true mutations. Variant allele fraction cutoffs were chosen as 0.15 for patients 1 and 3, and 0.11 for patient 2. Indels were then assigned to branches of the tree that they fitted perfectly. Indels that were assigned to the tree, along with their assignments, as well as indels that did not fit the tree are provided in Supplementary Data file S4. Rearrangements. The same rearrangement may be called in related samples with slightly different breakpoints. To identify rearrangements that had been sequenced in related clones as the same, both the upstream and the downstream breakpoints had to fall within 500 bp of each other. The majority of rearrangements fitted the tree. Visualization of discordant rearrangements using IGV 51 showed that often an overlapping rearrangement meant that the rearrangement was lost in a clone. All rearrangement calls that could and could not be assigned to the tree can be found in Supplementary Data file S4.
Timing substitutions and indels relative to a whole genome duplication (WGD).
A whole genome duplication was observed in the trunk of the tumour for patient 2. Substitutions. For substitutions, we aimed first to obtain an accurate estimate of the timing of WGD in molecular time, and second to time as many substitutions as possible relative to the WGD in order to perform signature analysis on them.
To obtain an estimate of the timing of the WGD, we examined substitutions in regions with two copies of one allele and none of the other (as determined by ASCAT). In these regions, if a mutation occurred before the WGD on that allele, it will be at copy number 2. If it occurred afterwards, it will be at copy number 1. One hundred and eighty substitutions occurred at copy number 2, and 67 at copy number 1. As at least half of the mutations that occurred before the WGD have been lost in such regions (as there is loss of one allele), the WGD can be estimated to have occurred at 84% ((180 × 2)/(180 × 2 + 67)) of molecular time in the trunk of the tumour (95% confidence interval of 80.8-87.6% calculated by bootstrapping 10,000 times).
Second, we wanted to time substitutions in regions with a greater range of copy number states for mutational signature analysis. To do this, for every truncal substitution in every tumour clone from patient 2, the copy number segment (as called by ASCAT) in which that mutation fell was defined. Mutations could be timed only in samples in which there was a minor copy number of 0 and a major copy number greater than 1. Fortunately, because of the extensive copy number changes in this tumour, all mutations fell in a region that met these criteria in at least one sample. For a given mutation that fell in such a copy number segment in a given sample, the VAF in that sample of known germline single nucleotide polymorphisms (SNPs) that fell in that segment (that necessarily occurred before the WGD) and the VAF of somatic mutations assigned to branches further down the tree (that necessarily occurred after the WGD) was examined. If, in a given sample, a mutation had a VAF greater than 90% of the VAFs of the mutations that were known to occur further down tree it was considered to have occurred before the WGD, whereas if it had a VAF less than 90% of the VAFs of the SNPs it was considered to have occurred after the WGD. If there was any overlap between the 90th percentiles of the SNPs and the later mutations, or if the mutation fitted neither of these criteria, it was considered uninformative and was not used in the signature analysis. This accounted for 9,094 mutations (out of a total of 12,623 assigned to the trunk) that were not used in signature analysis. There is no reason to believe that mutations that were excluded for these reasons should be attributable to different mutational signatures than those that could be included, and indeed their trinucleotide mutation contexts are similar (data not shown). For each mutation, then, the number of samples in which it had been counted before and after the WGD was tallied. If a mutation was called as occurring before the WGD in some samples and after the WGD in others, the mutation was designated as conflicting and excluded from the analysis. Eighty-two mutations fell into this category, and the remaining 3,447 could be timed unambiguously relative to the WGD and used in the signature analysis. In Fig. 1 we extrapolated the preWGD and postWGD fractions and their relative signature components to all mutations identified in the clonal trunk of P2. Mutations that were included in the signature analysis, those that were excluded as being uninformative, and those that were excluded as being conflicting, are reported in Supplementary Datafile S4. Indels. For indels, we simply aimed to estimate the proportion that occurred before and after the WGD, and so for this analysis we restricted ourselves to regions of the genome with copy number 2 + 0. An analogous approach to timing substitutions was taken, although rather than considering the distribution of germline indels and indels further down the tree, a hard VAF cutoff of 0.85 (which separated the bimodal distribution of indel VAFs in these loci) was used to define mutations as occurring before or after the WGD. Rearrangements. We timed rearrangements relative to the WGD in patient 2 by using the copy number step associated with deletions and tandem duplications in the trunk of this tumour, as determined by inspection of the change in read counts at breakpoints. The ratio of tandem duplications and deletions that had occurred before rather than after the WGD was extrapolated to give a ratio for all the rearrangements in the trunk, assuming that the relative proportion of different rearrangement classes stayed the same after the WGD. Driver mutations. Driver mutations in TP53 and APC were timed relative to the WGD in patient 2. The TP53 mutation was at VAF 1 in a region that was 2 + 0 in all samples, indicating that it occurred before the WGD. There were mutations in both alleles (which we will call mutation 1 and mutation 2) of APC. P2.T4.2 and P2.T5.1 both had the APC locus called as 2 + 2, and both mutations were at VAF 0.5. P2.T1.1, P2.T1.3, and P2.T6.2 were 2 + 1 in the APC region. Mutation 1 was at VAF 0.67 and mutation 2 at 0.33. In P2.T2.5 the region was also called as 2 + 1, but mutation 1 was at VAF 0.33 and mutation 2 at VAF 0.67. This shows biallelic inactivation of APC before the WGD. Assignment of samples to the tree based on targeted sequencing. Samples for which both WGS and targeted sequencing were available were used to estimate the sensitivity in the targeted data for finding substitutions that were identified in each branch by the WGS data. The targeted capture was designed against 360 cancer genes; in addition, all off-target reads that covered substitutions identified by WGS were considered. For example, in clone P1.T1.1, a fraction of 0.09 of all substitutions in the ultimate branch P1.T1.1 was found in the targeted data. Samples for which only targeted sequencing was available were then assigned to the ultimate branch of the tree with which they shared most substitutions. Driver analysis. To classify driver events in substitutions, indels and rearrangements we used the following criteria: 1) deleterious mutations in genes identified in CRC by TCGA 25 ; 2) all other known oncogenes carrying a canonical activating mutation; and 3) tumour suppressor genes with loss of function, and/ or carrying two deleterious mutations. A more inclusive approach for identifying functional mutations is listed in Supplementary Datafile S3 and described in the Supplementary Notes. Mutational signature analysis. Signature extraction based on non-negative matrix factorization was performed as previously described 32, 52 . Mutations in trinucleotide context were grouped according to branches of the phylogenetic tree or according to sample. Datasets were combined with data from 560 breast cancer genomes to increase performance of the NNMF procedure 53 . Expression analysis. Clustering analyses were based on FPKM values calculated with the Cufflinks algorithm 54 . To select informative genes for clustering we applied the following filters: FPKM > 1; coefficient of variation across all samples > 0.7 or absolute difference > 5. Subsequently, FPKM values were log 2 transformed and normalized. Normalization across samples was applied by subtracting the median expression value from individual expression values. Normalization across genes was applied by subtracting the gene's median expression from individual expression values. Normalized values were subjected to principle component analysis (PCA).
For each tumour clone we calculated a set of genes differentially expressed compared to all normal clones pooled together. Genes were called as differentially expressed if they had an FDR-corrected P value less than 0.05, resulting from a likelihood ratio test using a negative binomial generalized linear model fit with the R package 'edgeR' 55 . Raw counts were input into the edgeR model, along with normalization offsets calculated using the TMM method 56 . To construct the expression-based phylogenetic trees, we calculated Euclidean distances based on all genes that were differentially expressed in at least one tumour clone from that individual. Trees were inferred by the minimum evolution method, with the fast-me.bal function in the R-package 'ape' 57 . Methylation analysis. Methylation arrays were processed using the R package minfi 58 . We excluded three samples that failed standard QC metrics (more than 1,000 failed probes). We then excluded any probe from the analysis if it contained a variant identified in one of the samples, had a detection P value > 1 × 10 −10 in > 10% samples or one sample with P > 0.01, occurred at a location known to cross-hybridize with another genomic location, or where there was a known SNP at the CpG targeted by the probe. The remaining probes were then normalized either using the 'preprocessRaw' function when comparing all samples together or using the SWAN quantile-normalization method when comparing clones from a particular tumour 59 . The latter method is appropriate when the number of methylated probes is expected to be roughly constant across all samples, which was the case for each tumour. For all comparisons, M values (log 2 ratio of methylated to unmethylated probes) were calculated from the normalized probe intensities. Samples were clustered using PCA. For computational reasons, we used only the 1,000 most variable probes for PCA.
Probes that were differentially methylated between tumour and normal cells were identified using an F-test with variance shrinking and a false discovery rate of 0.01 via the 'dmpFinder' function comparing each tumour clone to all normal derived clones 58 . To construct the methylation-based phylogenetic trees, we calculated Euclidean distances based on probes that were differentially methylated in at least one tumour clone from that individual. For computational reasons, we used a q-value cutoff of 1 × 10 −8 for selection of informative probes. Trees were inferred by the minimum evolution method, with the fast-me.bal function in the R-package 'ape' 57 . Reporting summary. Further information on experimental design is available in the Nature Research Reporting Summary linked to this paper. Code availability. Mutation calling pipelines developed in house are available at https://github.com/cancerit. The Shearwater algorithm for deriving a background error model is available at: https://www.bioconductor.org/packages/devel/bioc/ vignettes/deepSNV/inst/doc/shearwaterML.html. The software for signature analysis used in this manuscript is available at: https://www.mathworks.com/ matlabcentral/fileexchange/38724-wtsi-mutational-signature-framework.
Custom R scripts developed for the analyses and visualizations in this manuscript are available from the authors on request. Data access. Sequencing data have been deposited at the European GenomePhenome Archive (http://www.ebi.ac.uk/ega/) under accession numbers EGAS00001000869 (targeted sequencing), EGAS00001000985 (RNA-seq) and EGAS00001000881 (WGS). RNA sequencing data of these organoid clones has also been described elsewhere 60 . Figs. 2-4 . A subclone derived from a tumour clone from P2 and its ancestor clone are circled. Right, phylogenetic trees based on expression data (as in Fig. 4b ) with the main branches used for our expression analysis indicated. b, P1, n = 20 biologically independent samples. c, P2, n = 22 biologically independent samples. d, P3, n = 17 biologically independent samples. e-g, Global analysis of expression changes attributed to the trunk of the tree, the main branches or subclonal variation. h, Venn diagram displaying the differentially expressed genes that were attributed to the trunk of each tumour. Differentially expressed genes determined by a likelihood ratio test using a negative binomial generalized linear model fit (FDR < 0.05). i-k, Comparison of differentially expressed genes identified in the organoid clones of each patient versus the original tissue sections. Only genes that were significantly altered in all clones or all biopsies from each individual are considered.
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Experimental design 1. Sample size
Describe how sample size was determined.
No statistical methods were used to predetermine sample size.
Data exclusions
Describe any data exclusions. We excluded one normal derived clone from P1 from our analysis. Although all characteristics (mutation numbers and signatures) were in the range of the other normals, we could not confirm that this clone was an independent sample or a subsample from P1.N.2. None of our conclusions would be affected by either including or excluding this sample.
Replication
Describe whether the experimental findings were reliably reproduced.
Drug response testing has been replicated and reliably reproduced (extended data figure 10)
Randomization
Describe how samples/organisms/participants were allocated into experimental groups.
Not relevant to this study; we describe each case on itself and do not make assumptions on groups that they represent.
Blinding
Describe whether the investigators were blinded to group allocation during data collection and/or analysis.
Investigators were blinded to each cloneID, but not individual's ID during data collection and analysis. The reason for this is that samples from the three individuals were collected at different timepoints -ie after they underwent surgery.
Note: all studies involving animals and/or human research participants must disclose whether blinding and randomization were used.
Statistical parameters
For all figures and tables that use statistical methods, confirm that the following items are present in relevant figure legends (or in the Methods section if additional space is needed).
n/a Confirmed
The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement (animals, litters, cultures, etc.)
A description of how samples were collected, noting whether measurements were taken from distinct samples or whether the same sample was measured repeatedly A statement indicating how many times each experiment was replicated
The statistical test(s) used and whether they are one-or two-sided (note: only common tests should be described solely by name; more complex techniques should be described in the Methods section)
A description of any assumptions or corrections, such as an adjustment for multiple comparisons
The test results (e.g. P values) given as exact values whenever possible and with confidence intervals noted A clear description of statistics including central tendency (e.g. median, mean) and variation (e.g. standard deviation, interquartile range)
Clearly defined error bars
See the web collection on statistics for biologists for further resources and guidance.
